Literature DB >> 14675685

Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study.

Cynthia D O'Malley1, Rosemary D Cress, Sharan L Campleman, Gary S Leiserowitz.   

Abstract

OBJECTIVE: The objective was to identify demographic, clinical, and provider characteristics that might influence cancer survival in a cohort of Northern California women using a population-based cancer registry.
METHODS: We used California Cancer Registry data to evaluate survival in 1051 Northern California women who were diagnosed with epithelial ovarian cancer between 1994 and 1996 and underwent a surgical procedure for their cancer. Chemotherapy data from the cancer registry were supplemented with a physician survey and medical record review. Database linkages with census and hospital discharge data provided socioeconomic and comorbidity measures. Kaplan-Meier method was used to generate survival curves and multivariate Cox proportional hazard models were used to evaluate the effect of different factors on survival.
RESULTS: Crude 5-year survival was 82, 57, 28, and 10% for women with FIGO stage IC, II, III, and IV disease, respectively. Adverse survival was most strongly influenced by advanced stages III and IV with a hazards ratio ranging from 8 to 11.8 compared to stage IC disease. Multivariate analysis also identified other adverse factors including high grade and other adverse histologies, age over 45, and rural location. Chemotherapy decreased the risk of death by 50% if the patient had advanced-stage disease. Medical comorbidity increased the risk of death by 40%. Survival was not influenced by race/ethnicity, socioeconomic status, physician specialty, or hospital characteristics.
CONCLUSION: Advanced age remains an adverse prognostic factor even after adjustment for treatment and comorbidity factors. These results also suggest that there may be important regional differences in ovarian cancer survival.

Entities:  

Mesh:

Year:  2003        PMID: 14675685     DOI: 10.1016/j.ygyno.2003.08.010

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  23 in total

1.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

2.  History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.

Authors:  Albina N Minlikeeva; Jo L Freudenheim; Rikki A Cannioto; J Brian Szender; Kevin H Eng; Francesmary Modugno; Roberta B Ness; Michael J LaMonte; Grace Friel; Brahm H Segal; Kunle Odunsi; Paul Mayor; Emese Zsiros; Barbara Schmalfeldt; Rüdiger Klapdor; Thilo Dӧrk; Peter Hillemanns; Linda E Kelemen; Martin Kӧbel; Helen Steed; Anna de Fazio; Susan J Jordan; Christina M Nagle; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Robert Edwards; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F Massuger; Jolanta Kupryjanczyk; Andrew Berchuck; Jenny Chang-Claude; Brenda Diergaarde; Penelope M Webb; Kirsten B Moysich
Journal:  Cancer Causes Control       Date:  2017-03-14       Impact factor: 2.506

3.  Rural-metropolitan disparities in ovarian cancer survival: a statewide population-based study.

Authors:  Jihye Park; Brenna E Blackburn; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kim Herget; Lindsay Burt; Theresa Werner; David K Gaffney; Ana Maria Lopez; Kathi Mooney; Mia Hashibe
Journal:  Ann Epidemiol       Date:  2018-04-12       Impact factor: 3.797

Review 4.  Centralisation of services for gynaecological cancer.

Authors:  Yin Ling Woo; Maria Kyrgiou; Andrew Bryant; Thomas Everett; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

5.  Impact of age on clinicopathological features and survival of epithelial ovarian neoplasms in reproductive age.

Authors:  Maya Hanatani; Nobuhisa Yoshikawa; Kosuke Yoshida; Satoshi Tamauchi; Yoshiki Ikeda; Kimihiro Nishino; Kaoru Niimi; Shiro Suzuki; Michiyasu Kawai; Hiroaki Kajiyama; Fumitaka Kikkawa
Journal:  Int J Clin Oncol       Date:  2019-09-20       Impact factor: 3.402

6.  Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.

Authors:  Robert E Bristow; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; William A Cliby
Journal:  J Natl Cancer Inst       Date:  2013-03-28       Impact factor: 13.506

7.  Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer.

Authors:  Mishka Terplan; Sarah Temkin; Ana Tergas; Ernst Lengyel
Journal:  Gynecol Oncol       Date:  2008-09-26       Impact factor: 5.482

8.  Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.

Authors:  John H Farley; Chunqiao Tian; G Scott Rose; Carol L Brown; Michael Birrer; G Larry Maxwell
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

9.  The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago.

Authors:  Charlotte E Joslin; Katherine C Brewer; Faith G Davis; Kent Hoskins; Caryn E Peterson; Heather A Pauls
Journal:  Gynecol Oncol       Date:  2014-08-28       Impact factor: 5.482

10.  Risk-scoring model for prediction of non-home discharge in epithelial ovarian cancer patients.

Authors:  Mariam M AlHilli; Christine W Tran; Carrie L Langstraat; Janice R Martin; Amy L Weaver; Michaela E McGree; Andrea Mariani; William A Cliby; Jamie N Bakkum-Gamez
Journal:  J Am Coll Surg       Date:  2013-06-29       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.